Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

460 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension.
Dahlöf B, Devereux RB, Julius S, Kjeldsen SE, Beevers G, de Faire U, Fyhrquist F, Hedner T, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Dahlöf B, et al. Among authors: nieminen ms. Hypertension. 1998 Dec;32(6):989-97. doi: 10.1161/01.hyp.32.6.989. Hypertension. 1998. PMID: 9856962 Clinical Trial.
Relation of QT interval and QT dispersion to echocardiographic left ventricular hypertrophy and geometric pattern in hypertensive patients. The LIFE study. The Losartan Intervention For Endpoint Reduction.
Oikarinen L, Nieminen MS, Viitasalo M, Toivonen L, Wachtell K, Papademetriou V, Jern S, Dahlöf B, Devereux RB, Okin PM. Oikarinen L, et al. Among authors: nieminen ms. J Hypertens. 2001 Oct;19(10):1883-91. doi: 10.1097/00004872-200110000-00025. J Hypertens. 2001. PMID: 11593111
Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study.
Reims HM, Kjeldsen SE, Brady WE, Dahlöf B, Devereux RB, Julius S, Beevers G, De Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Reims HM, et al. Among authors: nieminen ms. J Hum Hypertens. 2004 Jun;18(6):381-9. doi: 10.1038/sj.jhh.1001731. J Hum Hypertens. 2004. PMID: 15103313 Clinical Trial.
The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study.
Olsen MH, Wachtell K, Dahlöf B, Devereux RB, Ibsen H, Kjeldsen SE, Lindholm LH, Lyle PA, Nieminen MS. Olsen MH, et al. Among authors: nieminen ms. J Hum Hypertens. 2006 Jun;20(6):460-4. doi: 10.1038/sj.jhh.1002013. J Hum Hypertens. 2006. PMID: 16572193 Clinical Trial. No abstract available.
Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint.
Kjeldsen SE, Dahlöf B, Devereux RB, Julius S, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Kjeldsen SE, et al. Among authors: nieminen ms. Am J Hypertens. 2000 Aug;13(8):899-906. doi: 10.1016/s0895-7061(00)00280-6. Am J Hypertens. 2000. PMID: 10950398 Clinical Trial.
Left ventricular wall stresses and wall stress-mass-heart rate products in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint reduction in hypertension.
Devereux RB, Roman MJ, Palmieri V, Okin PM, Boman K, Gerdts E, Nieminen MS, Papademetriou V, Wachtell K, Dahlöf B. Devereux RB, et al. Among authors: nieminen ms. J Hypertens. 2000 Aug;18(8):1129-38. doi: 10.1097/00004872-200018080-00019. J Hypertens. 2000. PMID: 10954006 Clinical Trial.
460 results